2014
AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL
Gilbert M, Yuan Y, Wani K, Wu J, Omuro A, Lieberman F, Robins H, Gerstner E, Wu J, Wen P, Mikkelsen T, Armstrong T, Aldape K. AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL. Neuro-Oncology 2014, 16: v13-v13. PMCID: PMC4217801, DOI: 10.1093/neuonc/nou237.23.Peer-Reviewed Original ResearchDose-dense temozolomideClinical trialsPredictive markerFirst prospective clinical trialPhase II studyPrimary CNS tumorsProspective clinical trialsPossible predictive markerPotential predictive markerPatient reported outcomesSubsequent clinical trialsMGMT promoter statusMedian KPSMedian progressionPrimary endpointRecurrent diseaseII studyOverall survivalSymptom burdenMedian ageInitial treatmentCNS tumorsExtensive resectionStandard treatmentPRO collection
2012
High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma.
Welch M, Sauter C, Matasar M, Moskowitz C, Omuro A. High-dose chemotherapy (HDC) followed by autologous stem cell transplant (ASCT) for recurrent/progressive CNS lymphoma. Journal Of Clinical Oncology 2012, 30: 2089-2089. DOI: 10.1200/jco.2012.30.15_suppl.2089.Peer-Reviewed Original ResearchHigh-dose chemotherapyNon-Hodgkin lymphomaAutologous stem cell transplantHDC-ASCTPrimary CNS lymphomaCNS lymphomaRecurrent primary CNS lymphomaRefractory non-Hodgkin lymphomaSystemic non-Hodgkin lymphomaCytarabine-based regimensHigh-dose MTXStem cell transplantTime of recurrenceFebrile neutropeniaHD-ASCTInduction regimensCNS involvementCNS recurrenceCell transplantInitial presentationInitial treatmentR-EPOCHRetrospective reviewSalvage approachCNS disease
2010
Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
Kaloshi G, Sierra del Rio M, Ducray F, Psimaras D, Idbaih A, Laigle-Donadey F, Taillibert S, Houillier C, Dehais C, Omuro A, Sanson M, Delattre JY, Hoang-Xuan K. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. Journal Of Neuro-Oncology 2010, 100: 439-441. PMID: 20464625, DOI: 10.1007/s11060-010-0197-6.Peer-Reviewed Original ResearchConceptsLow-grade gliomasGrade gliomasProgressive low-grade gliomaTerms of PFSContrast enhancementEfficacy of nitrosoureasBetter PFSMedian PFSMedian OSObjective responseSalvage treatmentUpfront therapyMedian ageBetter prognosisInitial treatmentConventional radiotherapyChromosome 1p/19q codeletionNon-enhancing tumorResponse ratePatientsTemozolomidePure oligodendrogliomasPFSGliomasDisappointing results
2007
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report
Grimm S, Pulido J, Jahnke K, Schiff D, Hall A, Shenkier T, Siegal T, Doolittle N, Batchelor T, Herrlinger U, Neuwelt E, Laperriere N, Chamberlain M, Blay J, Ferreri A, Omuro A, Thiel E, Abrey L. Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Annals Of Oncology 2007, 18: 1851-1855. PMID: 17804469, DOI: 10.1093/annonc/mdm340.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsCombined Modality TherapyConsensusEye NeoplasmsFemaleHIV SeronegativityHumansLymphoma, Non-HodgkinMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsPrimary intraocular lymphomaOverall survivalMedian timeFocal therapyPrimary central nervous system lymphomaMedian ECOG performance statusCentral nervous system lymphomaTreatment typeECOG performance statusPositive CSF cytologyNervous system lymphomaBrain relapseMedian PFSMedian progressionPIOL patientsUncommon subsetIntraocular lymphomaPerformance statusRelapse patternsRetinal biopsyTreatment toxicityMedian ageSystem lymphomaInitial treatmentCSF cytology